Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Treasury Shares (2022 - 2025)

Historic Treasury Shares for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $2.4 million.

  • Entrada Therapeutics' Treasury Shares rose 1702.9% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 1702.9%. This contributed to the annual value of $2.0 million for FY2024, which is 5517.81% up from last year.
  • Per Entrada Therapeutics' latest filing, its Treasury Shares stood at $2.4 million for Q3 2025, which was up 1702.9% from $2.5 million recorded in Q2 2025.
  • Entrada Therapeutics' Treasury Shares' 5-year high stood at $2.7 million during Q1 2025, with a 5-year trough of $295104.0 in Q2 2022.
  • For the 4-year period, Entrada Therapeutics' Treasury Shares averaged around $1.4 million, with its median value being $1.3 million (2023).
  • As far as peak fluctuations go, Entrada Therapeutics' Treasury Shares soared by 19880.31% in 2024, and later skyrocketed by 1702.9% in 2025.
  • Quarter analysis of 4 years shows Entrada Therapeutics' Treasury Shares stood at $463964.0 in 2022, then soared by 173.4% to $1.3 million in 2023, then surged by 55.18% to $2.0 million in 2024, then rose by 19.78% to $2.4 million in 2025.
  • Its Treasury Shares stands at $2.4 million for Q3 2025, versus $2.5 million for Q2 2025 and $2.7 million for Q1 2025.